Shares of Xylem Inc. (XYL - Free Report) have declined 17.7% since the beginning of 2020. We believe that the price decline not only reflects investors’ reactions to the company’s dismal projections but also points toward the nervousness caused by the coronavirus outbreak.
The Rye Brook, NY-based company belongs to the Zacks Manufacturing – General Industrial industry, which, in turn, comes under the ambit of the Zacks Industrial Products sector. The industry is currently at the bottom 31% (with the rank of 175) of more than 250 Zacks industries.
Year to date, the company’s shares have dipped 17.7% compared with the industry’s decline of 33.6% and the sector’s fall of 30.9%. Notably, the S&P 500 has declined 23% during the same period.
The company currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Factors Affecting the Stock
Xylem reported in-line earnings results for fourth-quarter 2019, while lagged estimates by 0.7%. On a year-over-year basis, sales declined 1.1% year over year, with weakness in industrial and commercial end markets. Organic sales were flat in the quarter.
In addition to the lackluster performance, weak projections provided by Xylem must have added to the bearish sentiments for the stock. The company believes that organic sales will decline in low-single digits in the first half of 2020 due to strong year-over-year comparisons, soft orders and uncertainties related to the coronavirus outbreak in China. Organic sales are expected to be down 3-5% in the first quarter.
For the industrial market, Xylem believes that organic sales will be flat year over year in 2020 on geopolitical issues and economic uncertainty in the Middle East, soft short-cycle markets in North America in the first half, and soft mining/oil and gas markets. Also, flattish business in Europe might affect the company. For the commercial market, operating conditions are expected to be soft in the first half of the year.
Xylem expects 8-9% adjusted operating margin for first-quarter 2020. This compares unfavorably with 10.8% reported in the prior-year quarter. Also, it predicts earnings to be 40% of annual projection in the first half. Notably, it was 43% of annual earnings in the year-ago period.
Currently, the Zacks Consensus Estimate for Xylem’s earnings is pegged at $3.07 for 2020 and $3.46 for 2021, marking declines of 8.1% and 7% from the respective 60-day-ago figures. Notably, there were eight downward revisions in estimates for 2020 and six for 2021. No upward revision in estimates has been recorded for both years in the past 60 days.
Xylem Inc. Price and Consensus
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Shares of Xylem Inc. (XYL - Free Report) have declined 17.7% since the beginning of 2020. We believe that the price decline not only reflects investors’ reactions to the company’s dismal projections but also points toward the nervousness caused by the coronavirus outbreak.
The Rye Brook, NY-based company belongs to the Zacks Manufacturing – General Industrial industry, which, in turn, comes under the ambit of the Zacks Industrial Products sector. The industry is currently at the bottom 31% (with the rank of 175) of more than 250 Zacks industries.
Year to date, the company’s shares have dipped 17.7% compared with the industry’s decline of 33.6% and the sector’s fall of 30.9%. Notably, the S&P 500 has declined 23% during the same period.
The company currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Factors Affecting the Stock
Xylem reported in-line earnings results for fourth-quarter 2019, while lagged estimates by 0.7%. On a year-over-year basis, sales declined 1.1% year over year, with weakness in industrial and commercial end markets. Organic sales were flat in the quarter.
In addition to the lackluster performance, weak projections provided by Xylem must have added to the bearish sentiments for the stock. The company believes that organic sales will decline in low-single digits in the first half of 2020 due to strong year-over-year comparisons, soft orders and uncertainties related to the coronavirus outbreak in China. Organic sales are expected to be down 3-5% in the first quarter.
For the industrial market, Xylem believes that organic sales will be flat year over year in 2020 on geopolitical issues and economic uncertainty in the Middle East, soft short-cycle markets in North America in the first half, and soft mining/oil and gas markets. Also, flattish business in Europe might affect the company. For the commercial market, operating conditions are expected to be soft in the first half of the year.
Xylem expects 8-9% adjusted operating margin for first-quarter 2020. This compares unfavorably with 10.8% reported in the prior-year quarter. Also, it predicts earnings to be 40% of annual projection in the first half. Notably, it was 43% of annual earnings in the year-ago period.
Currently, the Zacks Consensus Estimate for Xylem’s earnings is pegged at $3.07 for 2020 and $3.46 for 2021, marking declines of 8.1% and 7% from the respective 60-day-ago figures. Notably, there were eight downward revisions in estimates for 2020 and six for 2021. No upward revision in estimates has been recorded for both years in the past 60 days.
Xylem Inc. Price and Consensus
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on NDSN - FREE
Get the latest research report on B - FREE
Get the latest research report on XYL - FREE
Get the latest research report on TNC - FREE